$2.34 Billion is the total value of Tekla Capital Management LLC's 203 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASRT | Exit | Assertio Therapeutics, Inc. | $0 | – | -1,000 | -100.0% | 0.00% | – |
| MNLO | Exit | Menlo Therapeutics Inc. | $0 | – | -24,784 | -100.0% | -0.01% | – |
| XENT | Exit | Intersect ENT, Inc. | $0 | – | -8,356 | -100.0% | -0.01% | – |
| TBPH | Exit | Theravance Biopharma, Inc. | $0 | – | -8,083 | -100.0% | -0.01% | – |
| TLGT | Exit | Teligent, Inc. | $0 | – | -101,458 | -100.0% | -0.02% | – |
| RMR | Exit | The RMR Group Inc.class a | $0 | – | -5,323 | -100.0% | -0.02% | – |
| NLNK | Exit | NewLink Genetics Corporation | $0 | – | -205,026 | -100.0% | -0.02% | – |
| ECYT | Exit | Endocyte, Inc. | $0 | – | -41,980 | -100.0% | -0.03% | – |
| ARGX | Exit | argenx SEsponsored adr | $0 | – | -15,188 | -100.0% | -0.04% | – |
| CBAY | Exit | CymaBay Therapeutics, Inc. | $0 | – | -169,962 | -100.0% | -0.07% | – |
| RVNC | Exit | Revance Therapeutics, Inc. | $0 | – | -77,919 | -100.0% | -0.07% | – |
| ACAD | Exit | ACADIA Pharmaceuticals Inc. | $0 | – | -93,689 | -100.0% | -0.07% | – |
| RGEN | Exit | Repligen Corporation | $0 | – | -38,700 | -100.0% | -0.08% | – |
| HSIC | Exit | Henry Schein, Inc. | $0 | – | -31,400 | -100.0% | -0.10% | – |
| HZNP | Exit | Horizon Pharma plcshares | $0 | – | -162,900 | -100.0% | -0.12% | – |
| TSRO | Exit | TESARO, Inc. | $0 | – | -94,970 | -100.0% | -0.13% | – |
| ESRX | Exit | Express Scripts Holding Company | $0 | – | -53,250 | -100.0% | -0.18% | – |
| CI | Exit | Cigna Corporation | $0 | – | -40,461 | -100.0% | -0.31% | – |
| AET | Exit | Aetna Inc. | $0 | – | -83,637 | -100.0% | -0.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.